Blog

  • ‘How woke is Hollywood going to make this character?’: Dean Cain criticises new Superman movie | Film

    ‘How woke is Hollywood going to make this character?’: Dean Cain criticises new Superman movie | Film

    Dean Cain, who played the Man of Steel in the 1990s TV series Lois & Clark: The New Adventures of Superman, has claimed the new Superman movie directed by James Gunn is “woke”.

    Cain, a vocal supporter of Donald Trump, was speaking to TMZ and said: “How woke is Hollywood going to make this character? How much is Disney going to change their Snow White? Why are they going to change these characters [to] exist for the times?”

    Cain was responding to comments by Gunn published on Friday in the Times, in which the director said: “Superman is the story of America … An immigrant that came from other places and populated the country, but for me it is mostly a story that says basic human kindness is a value and is something we have lost.”

    Cain added: “We know Superman is an immigrant – he’s a freaking alien … The ‘American way’ is immigrant friendly, tremendously immigrant friendly. But there are rules … You can’t come in saying: ‘I want to get rid of all the rules in America, because I want it to be more like Somalia.’ Well that doesn’t work, because you had to leave Somalia to come here … There have to be limits, because we can’t have everybody in the United States. We can’t have everybody, society will fail. So there have to be limits.”

    Superman has become the focus of criticism from some rightwing commentators, including Fox News’ host Jesse Watters, who suggested that Superman “fights for truth, justice, and your preferred pronouns” and that gang moniker MS-13 was “superimposed” on his cape.

    At the film’s premiere on Monday, Gunn sought to defuse any controversy saying: “I think this is a movie about kindness and I think that’s something everyone can relate to.”

    Gunn’s actor brother Sean, who appears in Superman as billionaire Maxwell Lord, addressed the issue directly, saying: “It is exactly what the movie is about. We support our people, you know? We love our immigrants. Yes, Superman is an immigrant, and yes, the people that we support in this country are immigrants and if you don’t like that, you’re not American. People who say no to immigrants are against the American way.”

    Continue Reading

  • Brussel’s omnibus proposal risks making the EU less competitive – Green Central Banking

    1. Brussel’s omnibus proposal risks making the EU less competitive  Green Central Banking
    2. EU Simplifies Sustainability Taxonomy to Ease ESG Compliance and Support Carbon Neutral Strategy  Seneca ESG
    3. EU Sustainability Reporting Unpacked: Latest Developments on the Omnibus Package and ISSB Interoperability  JD Supra
    4. European Commission Significantly Cuts Back Taxonomy Reporting – A Look at the July 4 Delegated Regulation  Ropes & Gray LLP

    Continue Reading

  • Sri Lanka vs Bangladesh 1st T20I Live Streaming: When And Where To Watch

    Sri Lanka vs Bangladesh 1st T20I Live Streaming: When And Where To Watch

    Sri Lanka vs Bangladesh 1st T20I Live Streaming

    Photo : AP

    After losing the Test and ODI series, Bangladesh would aim to win the T20I series and end the Sri Lanka tour on a high. Bangladesh have been competitive in the white-ball leg, winning the second ODI by 16 runs; however, the hosts have been in far better form and won the first and last ODIs to win the series.

    The T20I series should be far more competitive as both teams are very comfortable in the format. Sri Lanka suffered a massive blow ahead of the series as ace all-rounder Wanindu Hasaranga was ruled out.

    Here Is All You Need To Know About The SL vs BAN T20I Series

    When Will Sri Lanka vs Bangladesh 1st T20I Be Played?

    The first T20I between Sri Lanka vs Bangladesh will be played today (Thursday, July 10).

    Where Will Sri Lanka vs Bangladesh 1st T20I Be Played?

    The first T20I between Sri Lanka vs Bangladesh T20I will be played at the Pallekele International Cricket Stadium.

    What Time Will The First Sri Lanka vs Bangladesh T20I Start?

    The first Sri Lanka Vs Bangladesh T20I will begin at 7:00 PM IST. The toss for the first T20I between Sri Lanka and Bangladesh will be held at 6:30 PM IST.

    Where To Watch Live Telecast Of Sri Lanka vs Bangladesh T20I In India?

    The first Sri Lanka vs Bangladesh T20I will be televised live on the Sony Sports Network in India.

    Where To Watch Live Stream Of Sri Lanka vs Bangladesh T20I In India?

    The first Sri Lanka vs Bangladesh T20I will be streamed live on the SonyLIV and FanCode apps and websites.

    SL vs BAN T20I Squads

    Sri Lanka Squad: Pathum Nissanka, Kusal Mendis(w), Kusal Perera, Kamindu Mendis, Charith Asalanka(c), Dasun Shanaka, Dunith Wellalage, Maheesh Theekshana, Binura Fernando, Matheesha Pathirana, Nuwan Thushara, Jeffrey Vandersay, Dinesh Chandimal, Chamika Karunaratne, Eshan Malinga, Avishka Fernando.

    Bangladesh Squad: Tanzid Hasan Tamim, Parvez Hossain Emon, Litton Das(w/c), Towhid Hridoy, Shamim Hossain, Jaker Ali, Mehidy Hasan Miraz, Tanzim Hasan Sakib, Rishad Hossain, Taskin Ahmed, Mustafizur Rahman, Nasum Ahmed, Mohammad Saifuddin, Mahedi Hasan, Mohammad Naim, Shoriful Islam.


    Continue Reading

  • Everything you need to know about The Ocean Race Europe 2025 – The Ocean Race

    1. Everything you need to know about The Ocean Race Europe 2025  The Ocean Race
    2. The Ocean Race Europe stops in Nice: three days of sea, science, and offshore racing  nice-premium.com
    3. New tech for offshore racing audience  Scuttlebutt Sailing News
    4. The Ocean Race Europe: the Paprec Arkéa crew is ready to take on the challenge!  The Ocean Race
    5. Biotherm arrives in Kiel Start of The Ocean Race Europe on August 10  The Ocean Race

    Continue Reading

  • AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

    AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

    AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

    • ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)

    NORTH CHICAGO, Ill. and NEW YORK, July 10, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT® protein platform, for oncology and autoimmune diseases.

    “Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper, more durable responses by engaging multiple targets simultaneously,” said Roopal Thakkar, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “This partnership with IGI reflects our unwavering commitment to advancing novel therapies for patients with multiple myeloma, a disease where significant unmet need remains despite recent progress.”

    “ISB 2001 exemplifies the potential of our BEAT® protein platform to generate effective multispecifics that may overcome resistance and improve outcomes in hard-to-treat cancers,” said Cyril Konto, M.D., President and CEO of IGI. “This agreement marks a defining milestone in IGI’s scientific journey and reflects our team’s deep commitment to delivering meaningful therapies for patients. Our partnership with AbbVie accelerates ISB 2001’s path to patients and sharpens our focus on advancing the next generation of BEAT®-enabled assets in oncology.”

    Under the terms of the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan and Greater China. Subject to regulatory clearance, IGI will receive an upfront payment of $700 million and is eligible to receive up to $1.225 billion in development, regulatory, and commercial milestone payments, along with tiered, double-digit royalties on net sales.

    About AbbVie

    AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

    About AbbVie in Oncology

    AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

    Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world’s most widespread and debilitating cancers. As we work to have a remarkable impact on people’s lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

    About ISB 2001

    ISB 2001 is a first-in-class trispecific T-cell engager that targets BCMA and CD38 on myeloma cells and CD3 on T cells currently in Phase 1 for relapsed/refractory multiple myeloma. Developed using IGI’s proprietary BEAT® protein platform, ISB 2001 was engineered with two distinct binders against myeloma-associated antigens to enhance avidity, even at low target expression levels, while aiming to improve safety over first-generation bispecific antibodies.  Recently presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as a Rapid Oral Presentation (Abstract #7514), data from 35 patients demonstrated a sustained overall response rate (ORR) of 79% and a high complete/stringent complete response (CR/sCR) rate of 30% at active doses ≥ 50 µg/kg in a heavily pretreated population of relapsed/refractory myeloma patients, with a favorable safety profile.

    U.S. Food & Drug Administration granted ISB 2001 Orphan Drug Designation in July 2023 and Fast Track Designation for the treatment of relapsed/refractory myeloma patients in May 2025. 

    About the BEAT® Multispecific™ Platform

    IGI’s proprietary BEAT® platform goes beyond traditional bispecific antibody approaches, addressing key engineering bottlenecks that have historically limited large-scale bispecific production. By leveraging a proprietary common light chain library and TCR interface-based heavy chain pairing, BEAT® enables the development of next-generation immune cell engagers with strong therapeutic potential in oncology. Unlike many engineered formats, BEAT® mirrors the architecture of natural antibodies utilizing both light and heavy chains to enhance stability and function. Key attributes of the BEAT® platform include its multispecific versatility, enabling the design of antibodies that engage diverse immune cell types such as T cells, myeloid cells, and NK cells against multiple antigens. The platform also features optimized engineering through high-fidelity heavy chain pairing with a common light chain, allowing for precise Fc modulation and access to a broad structural design space. Additionally, BEAT® supports robust manufacturability, producing correctly assembled multispecific antibodies with favorable stability, extended half-lives, low immunogenicity and high titer yields through standardized process development and manufacturing operations.

    About IGI 

    IGI is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class multispecificsTM aimed at addressing complex diseases and treating patients holistically. Powered by its proprietary BEAT® technology platform, IGI is committed to delivering breakthrough, curative therapies to improve and extend the lives of patients battling hematological malignancies and solid tumors. For more information, visit www.IGInnovate.com.

    AbbVie Forward-Looking Statements

    Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

     

     

    SOURCE AbbVie


    Continue Reading

  • How artificial intelligence is reprogramming the future of games

    How artificial intelligence is reprogramming the future of games

    Artificial intelligence has been transforming the world in recent years across nearly every field, from medicine and education to transportation, finance, design, and art. In the gaming industry, one of the most creative and fastest-growing sectors, it is driving profound change: it’s no longer just about advanced graphics or new combat mechanics, but about a sweeping revolution that brings intelligent characters, real-time story generation, and personalized experiences that reshape the relationship between player and game.

    AI not only upgrades the look of characters and generates new worlds, it is also changing workflows, transforming business models, and, most importantly, creating a more personalized and complex gaming experience than ever before.

    1 View gallery

    מימין שחר סורק CMO ב Overwolf ו אורי רובין CTO ב פלייטיקה

    Uri Rubin (left) and Shahar Sorek.

    (Photos: Tom Simon, Ohad Romano)

    A 2022 Deloitte report showed that more than 70% of large game development companies had already set up dedicated AI teams working across departments. These teams are responsible for developing and implementing AI technologies while overseeing internal governance and quality control.

    Ubisoft, for example, uses Ghostwriter to write initial dialogue for NPCs (non-player characters), saving the writing team hundreds of hours and freeing them to craft richer, more complex storylines. EA, for its part, uses AI models to detect bugs and test game balance, dramatically shortening testing cycles while maintaining product stability over time.

    This trend is also evident in Israel. Uri Rubin, CTO at Playtika, says the company is adapting its operations to meet new realities. “One of the best examples is moving an independent business unit (studio) into the technology division,” he says. “Changing an organizational culture that has existed for years requires external momentum, and that’s exactly what AI provides. The idea is to break out of the traditional structure where the studio and technology teams work separately, and instead combine forces with a shared focus. For the first time, teams are working together toward one goal.”

    Rubin notes that integrating AI into the studio’s workflows allows the company to deliver more precise and efficient solutions: “This change ensures that the studio and technology teams stay aligned and focused on shared tasks. We’re learning as we go and believe that if this transformation succeeds, we can replicate it across other units.”

    According to Shahar Sorek, CMO at Overwolf, “Every department in the company already uses AI. In my department alone, we rely on at least ten different tools daily – for design, writing, video editing, supporting internal workflows, and even accelerating coding. These tools let us work at a much larger scale.”

    However, Sorek stresses that adopting AI requires extra caution for sensitive tasks, especially those involving a product’s core elements. “The more critical the product, like the code, game engine, or sensitive data, the more carefully you need to introduce AI. After all, it’s not your own tool, it’s not built in-house, and you can’t always know where your exposed data might end up or how it could be used.”

    Despite the enormous savings in time and resources, Sorek insists the new technology does not come at the expense of human workers. “I’m not laying people off,” he clarifies. “The more complex the product, the more people you still need.”

    “Technology isn’t going to replace people, it’s going to upgrade them,” Rubin adds. “We’ll always need the human factor on every team, but at the same time, AI will play a significant role in informing decisions. AI will handle tedious, repetitive tasks and free up teams for creativity, critical thinking, and faster, more dynamic decision-making.”

    Where the industry once focused on linear, fixed, and predefined games, AI is now making gameplay dynamic, multi-layered, and deeply personal. There are already plenty of examples that show how far the technology has come.

    In Minecraft, for instance, the world’s best-selling game, modding communities (independent developers who expand the base game) have created AI-powered add-ons that let players generate entire worlds automatically. The player simply enters a short description, for example, “a medieval-style underground dungeon with traps and rare creatures,” and the system builds it in minutes, complete with enemies, quests, hidden items, and surprises. Such add-ons have become especially popular on private servers, where developers craft unique adventures for each player or group.

    There’s also been a major leap in NPC technology. Inworld AI, an American company, has developed a platform for creating interactive characters that understand context, retain memory, and can hold complex conversations with players. These characters learn player behavior and adapt their responses in real time, expressing emotions, responding with humor or anger, and maintaining a history of interactions so players can enjoy long, playful exchanges or even philosophical debates.

    Ubisoft has also integrated characters whose shifting personalities affect how the entire game unfolds: if a player chooses a violent approach with an NPC, the game opens new subplots that can change the ending entirely.

    CD Projekt Red, the developer behind Cyberpunk 2077, is experimenting with AI systems that track players’ play styles over time. If a player often helps weaker characters, the game will offer more emotional and layered plots; if they play aggressively, it will unlock storylines packed with battles and challenges.

    “The goal is for every player to ultimately have an experience tailored to their preferences and play style,” says Rubin. “AI will help us produce far more content, giving players a richer, more personalized experience.”

    Sorek believes the next big leap will be full-game generation, an AI engine that receives a general prompt and builds an entire custom game. “The AI will learn who you are, what you like, and generate a game for you as you play,” he says. “Of course, there are still challenges, games are complex, both visually and emotionally. The AI isn’t quite there yet, but we’re getting closer. New companies are already developing AI that can manage interactions, build mini-games, and even run entire game engines.”

    Continue Reading

  • Brazil vows to match US tariffs after Trump threatens 50% levy

    Brazil vows to match US tariffs after Trump threatens 50% levy

    Brazilian President Luiz Inácio Lula da Silva has said he is ready to match any tariffs imposed on Brazil by the United States.

    Lula was responding to Wednesday’s threat by his US counterpart, Donald Trump, to impose a 50% import tax on Brazilian goods from 1 August.

    In a letter, Trump cited Brazil’s treatment of former President Jair Bolsonaro as a trigger for tariff-hike.

    Bolsonaro is currently on trial for allegedly attempting to stage a coup against Lula after being defeated by him in the 2022 election.

    Trump referred to Bolsonaro as “a highly respected leader throughout the world”. “This Trial should not be taking place,” he wrote, calling on Brazil to immediately end the “witch hunt” against the former president.

    Trump’s support for Bolsonaro does not come as a surprise as the two men have long been considered allies.

    The US president had already slammed Brazil for its treatment of Bolsonaro on Monday, comparing it to the legal cases he himself had faced in US courts.

    The 50% tariff threat was met with a robust and lengthy response by President Lula.

    In a post on X, he stressed that Brazil was “a sovereign country with independent institutions and will not accept any tutelage”.

    The Brazilian leader also announced that “any unilateral tariff increases” would be met with reciprocal tariffs imposed on US goods.

    The US is Brazil’s second-largest trade partner after China, so the hike from a tariff rate of 10% to an eye-watering 50% – if it comes into force – would hit the South American nation hard.

    But Lula also made a point of challenging Trump’s assertion that the US had a trade deficit with Brazil, calling it “inaccurate”.

    Lula’s rebuttal is backed up by US government data, which suggests the US had a goods trade surplus with Brazil of $7.4bn (£5.4bn) in 2024.

    Brazil is the US’s 15th largest trading partner and among its main imports from the US are mineral fuels, aircraft and machinery.

    For its part, the US imports gas and petroleum, iron, and coffee from Brazil.

    Brazil was not the only country Trump threatened with higher tariffs on Wednesday.

    Japan, South Korea and Sri Lanka were among 22 nations which received letters warning of higher levies.

    But the letter Trump sent to his Brazilian counterpart was the only one focussing matters beyond alleged trade deficits.

    As well as denouncing the treatment of ex-President Bolsonaro, Trump slammed what he said were “secret and unlawful censorship orders to US social media platforms” which he said Brazil had imposed.

    Trump Media, which operates the US president’s Truth Social platform and is majority-owned by him, is among the US tech companies fighting Brazilian court rulings over orders suspending social media accounts.

    Lula fought back on that front too, justifying the rulings by arguing that “Brazilian society rejects hateful content, racism, child pornography, scams, fraud, and speeches against human rights and democratic freedom”.

    Rafael Cortez, a political scientist with Brazilian consulting firm Tendências Consultoria, told BBC News Brasil that rather than hurt him, the overly political tone of Trump’s letter could end up benefitting Lula.

    “Those confronting Trump win at home when Trump and other conservative leaders speak out on issues pertaining to their countries. That happened, to a certain degree, in Mexico, and the elections in Canada and Australia,” Mr Cortez says of other leaders who have challenged Trump and reaped the rewards in the form of rising popularity levels.

    Creomar de Souza of the political risk consultancy Dharma Politics told BBC News Mundo’s Mariana Schreiber that it would depend on the Lula government coming up with organised and united response if it is to “score a goal” against Trump.

    Continue Reading

  • Laparoscopic Management of a Rare Lesser Sac Internal Hernia Involving the Terminal Ileum and Entire Right Colon: A Diagnostic and Surgical Challenge

    Laparoscopic Management of a Rare Lesser Sac Internal Hernia Involving the Terminal Ileum and Entire Right Colon: A Diagnostic and Surgical Challenge


    Continue Reading

  • Researchers create map of how body parts interact under stress, can help diagnose illness earlier

    Researchers create map of how body parts interact under stress, can help diagnose illness earlier

    The study encourages a “whole-body” view of physiology, instead of focusing on isolated measurements such as heart or breathing rate |Image used for representational purpose only
    | Photo Credit: Getty Images/iStockphoto

    A new study has mapped how different body parts communicate with each other under physiological stress, such as during exercise or sleep deprivation, which researchers say could one day help diagnose an illness earlier. Researchers at the University of Portsmouth and University College London, UK, said the study encourages a “whole-body” view of physiology, instead of focusing on isolated measurements such as heart or breathing rate.

    Using ‘transfer entropy’ — a method of monitoring body signals — a complex network of maps was created showing which body parts act as ‘information hubs’ under different stress conditions, the team explained.

    For example, during exercise, the heart — which is working hard to pump blood to muscles — receives the most input from other systems and therefore, “takes the lead” in helping the body adapt, the researchers said.

    Described in a study published in the Journal of Physiology, the maps “show that our body isn’t just reacting to one thing at a time,” said author Alireza Mani, associate professor and head of the network physiology lab at University College London.

    “It’s responding in an integrated, intelligent way. And by mapping this, we’re learning what normal patterns look like, so we can start spotting when things go wrong,” Mani said.

    Organ systems are known to work together to help one adapt and function under conditions that produce stress in the body.

    The study looked at 22 healthy volunteers who were monitored using wearable sensors during exposure to three stressed environments — low oxygen (hypoxia), sleep deprivation and physical moderate intensity exercise (cycling).

    A face mask measured the participants’ breathing gases, while a pulse oximeter tracked blood oxygen levels.

    The researchers analysed the signals recorded — heart and respiratory rate, blood oxygen levels, and concentration of oxygen and carbon dioxide in exhaled breath — and tracked how information was being transferred between the organ systems.

    In a low oxygen environment, blood oxygen becomes the “central player”, working closely with breathing to adjust to the lack of air, the researchers said. They explained that when sleep deprivation is added, the changes are more subtle, with information shifting between organ systems — if low oxygen is also involved, breathing rate suddenly steps up and takes the lead.

    The maps indicate early, hidden signs of stress that would not be obvious from heart rate or oxygen levels alone, meaning that the findings could one day help spot health problems before symptoms appear, the team said.

    “This matters in healthcare because early signs of deterioration, especially in intensive care units or during the onset of complex conditions like sepsis or COVID-19, often show up not in the average numbers but in the way those numbers relate to each other,” Mani said. The authors wrote, “During exercise, heart rate emerged as the primary recipient of information, whereas (blood oxygen) served as the main disseminator. Hypoxia led to the engagement of (blood oxygen) as a hub in the network.”

    “Sleep deprivation was associated with a shift in the flow of information between the nodes during hypoxia,” they wrote.

    Published – July 10, 2025 04:54 pm IST

    Continue Reading

  • Lipoprotein Exposure Before 40 Predicts Future Heart Risk

    Lipoprotein Exposure Before 40 Predicts Future Heart Risk

    TOPLINE:

    For adults younger than 40 years, higher cumulative exposure to atherogenic lipoprotein particles — apolipoprotein B, low-density lipoprotein particles, and triglyceride-rich lipoprotein particles — was associated with a significant increase in the risk for atherosclerotic cardiovascular disease (ASCVD) after 40 years of age.

    METHODOLOGY: 

    • Researchers analyzed prospective data from a population-based cohort study of US adults (n = 5115; 55% women) to examine whether exposure to atherogenic lipoprotein particles during early adulthood was linked to ASCVD in midlife.
    • They evaluated the levels of atherogenic lipoprotein particles — apolipoprotein B, low-density lipoprotein particles, and triglyceride-rich lipoprotein particles — in 4366 participants aged 18-40 years to calculate the cumulative exposure over 22 years.
    • ASCVD events — fatal and nonfatal myocardial infarction and stroke — occurring after age 40 were tracked over a mean follow-up of 19.3 years.

    TAKEAWAY:

    • Each SD increase in cumulative exposure to atherogenic lipoprotein particles was associated with a 28%-30% higher risk for ASCVD after age 40; adjusted hazard ratios were 1.30 (95% CI, 1.15-1.46) for apolipoprotein B, 1.28 (95% CI, 1.13-1.44) for low-density lipoprotein particles, and 1.28 (95% CI, 1.13-1.45) for triglyceride-rich lipoprotein particles.
    • The risk for ASCVD increased notably when usual exposure exceeded 75 mg/dL/y for apolipoprotein B, 1000 nmol/L/y for low-density lipoprotein particles, and 135 nmol/L/y for triglyceride-rich lipoprotein particles.
    • The risk for ASCVD after age 40 was generally linear when each atherogenic lipoprotein particle was examined separately.

    IN PRACTICE:

    “Data presented from the current analysis from one US-based cohort study of young adults offer potential clinical thresholds, rather than definitive cutoff values for clinical practice,” the researchers of the study noted.

    “While clinical validation is needed, these values could serve as reasonable targets for untreated young adults, and achieving them may require both individual-level interventions — such as lifestyle modification and pharmacotherapy — as well as policy-level strategies, including subsidies for nutritious foods and public health initiatives to promote physical activity,” they added.

    SOURCE:

    This study was led by Alexander R. Zheutlin, MD, Northwestern University Feinberg School of Medicine, Chicago. It was published online on July 4, 2025, in the European Heart Journal.

    LIMITATIONS:

    Many clinical practices lacked the ability to measure specific subfractions of lipoprotein particles. Children were not included in this study, despite evidence of childhood exposure to lipid particles predicting heart disease risk in adult life. This study was not sufficiently powered to stratify risks based on race and gender.

    DISCLOSURES:

    The original cohort study was supported by the National Heart, Lung, and Blood Institute in collaboration with the University of Alabama, Northwestern University, University of Minnesota, and Kaiser Foundation Research Institute. One author reported receiving funding from the National Institutes of Health and personal fees from 3M.

    This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

    Continue Reading